Rapid Micro Biosystems (RPID) AI Stock Analysis

• Market Cap: $124.67M
• Dividend Yield: N/A
• Average Volume (3M): 104.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 22.57%
• EPS Growth: 14.11%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.27
• Shares Outstanding: 39,710,800
• 10 Day Avg. Volume: 132,535
• 30 Day Avg. Volume: 104,342
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 4.24
• Enterprise Value/Gross Profit: 22.41
• Enterprise Value/Ebitda: -2.92
• 1Y Price Target: $5.25
• Price Target Upside: 100.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 47 Neutral
• Price Target: $2.50 ▼(-4.58% Downside)

Rapid Micro Biosystems' overall stock score is primarily impacted by its financial challenges, including persistent losses and negative cash flows. The technical indicators suggest a bearish trend, further weighing on the score. However, the earnings call and recent corporate events provide some positive outlook, with revenue growth and strategic collaborations offering potential for future improvement.

Positive Factors

Customer Adoption

A 2023 Company-led survey of 146 pharma professionals found 93% were open to adopting Rapid Microbial Methods, citing faster batch release, reduced manual labor, and improved integration with workflows.

Market Leadership

Rapid Micro Biosystems is emerging as the category leader in microbial quality control automation with its Growth Direct platform, a system that compresses testing timelines from weeks to days, reduces contamination risk, and ensures compliance with increasingly strict regulatory requirements.

Recurring Revenue

Recurring revenue now represents over 55% of total revenue, which includes consumables that carry a ~60% gross margin.

Negative Factors

Spending Uncertainty

Spending uncertainty and tariff impact are driving expectations toward the lower end of 21-25 placements.

Stock Market Reaction

The selloff following the Q2 print is viewed as underappreciating the strong growth outlook for Rapid with multiple avenues to outperform.

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems (RPID) is a biotechnology company specializing in the development and commercialization of innovative products for the detection of microbial contamination in the production of pharmaceuticals, biotechnology products, and personal care products. The company's core products include automated, non-destructive microbial detection systems that provide rapid and accurate results, enabling manufacturers to ensure product safety and quality while streamlining their quality control processes.

How the Company Makes Money

Rapid Micro Biosystems generates revenue primarily through the sale of its automated microbial detection systems and related consumables. The company offers a range of products designed to improve the efficiency and effectiveness of microbial contamination testing in manufacturing environments. Revenue streams include the initial sale of detection instruments, ongoing sales of consumable testing materials required for regular system operation, and service agreements for maintenance and support. Additionally, the company may engage in strategic partnerships with pharmaceutical and biotechnology firms to enhance its market reach and leverage collaborative opportunities.

Rapid Micro Biosystems Financial Statement Overview

Summary

Rapid Micro Biosystems shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is stable with a strong equity base, but operational inefficiencies and consistent net losses present challenges. Improvement in margins and cash flow management is needed.

Income Statement

The company has shown consistent revenue growth, with a significant revenue growth rate of 9.8% in the TTM (Trailing-Twelve-Months). However, profitability metrics are concerning, with negative gross profit margin of 12.1% and net profit margin of -151.2% in the TTM. The EBIT and EBITDA margins are also negative, indicating operational challenges and high operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 76.6% in the TTM, showcasing financial stability. However, the debt-to-equity ratio is low at 0.09, indicating limited leverage, which can be both a strength and a limitation for growth. However, the return on equity is negative due to persistent net losses, indicating inefficiencies in generating returns from shareholder equity.

Cash Flow

The company faces cash flow challenges with negative operating and free cash flows. The operating cash flow to net income ratio is 0.84, which suggests that cash generation remains a challenge despite net income levels. Additionally, the free cash flow growth rate is negative, indicating a worsening free cash flow situation over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.29M	28.05M	22.52M	17.13M	23.23M	16.08M
Gross Profit	5.73M	-109.00K	-5.49M	-8.54M	-7.74M	-8.07M
EBITDA	-43.92M	-46.56M	-53.46M	-60.38M	-45.80M	-32.00M
Net Income	-44.11M	-46.89M	-52.47M	-60.81M	-73.52M	-37.08M
Balance Sheet
Total Assets	75.59M	98.17M	143.45M	190.65M	241.17M	70.00M
Cash, Cash Equivalents and Short-Term Investments	31.25M	50.73M	92.05M	108.65M	193.50M	45.08M
Total Debt	5.58M	6.17M	7.35M	7.97M	400.00K	24.81M
Total Liabilities	21.04M	22.82M	25.46M	26.48M	20.19M	45.18M
Stockholders Equity	54.55M	75.35M	117.99M	164.17M	220.98M	24.82M
Cash Flow
Free Cash Flow	-38.28M	-45.52M	-46.93M	-65.29M	-58.18M	-31.69M
Operating Cash Flow	-37.27M	-44.15M	-45.08M	-58.55M	-54.96M	-31.00M
Investing Cash Flow	18.35M	36.66M	42.15M	-93.47M	-13.29M	-15.67M
Financing Cash Flow	136.00K	203.00K	149.00K	693.00K	216.75M	64.23M

Rapid Micro Biosystems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Negative. The current price of 2.62 is below the 20-day moving average (MA) of 3.46, below the 50-day MA of 3.46, and above the 200-day MA of 2.39, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 33.90 is Neutral, neither overbought nor oversold. The STOCH value of 29.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPID.

Rapid Micro Biosystems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	77 Outperform	$95.72M	12.36	5.00%	―	0.29%	-22.13%
SRTS	57 Neutral	$56.55M	48.68	-1.62%	―	3.30%	-112.70%
MASS	56 Neutral	$255.13M	―	-46.85%	―	14.65%	-86.36%
XTNT	54 Neutral	$84.74M	―	-9.80%	―	15.16%	-39.18%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
RPID	47 Neutral	$124.67M	―	-59.15%	―	22.57%	14.11%

Rapid Micro Biosystems Corporate Events

Rapid Micro Biosystems Secures $45M Loan for Growth

On August 8, 2025, Rapid Micro Biosystems entered into a Loan and Security Agreement with Trinity Capital Inc., securing a $45 million term loan facility to bolster its financial position and support long-term growth. The company reported a 10% increase in total revenue for the second quarter of 2025 compared to the previous year, driven by strong performance in service and product revenue, and reaffirmed its full-year revenue guidance of at least $32 million.

The most recent analyst rating on (RPID) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.

Rapid Micro Biosystems CEO Diagnosed with Lymphoma

On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.

The most recent analyst rating on (RPID) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.

Rapid Micro Biosystems Board Resignation and Elections

On May 22, 2025, Jeffrey Schwartz resigned from the board of directors of Rapid Micro Biosystems, where he served since April 2018, without any disagreements with the company. During the company’s annual meeting on the same day, stockholders elected Dafni Bika and Inese Lowenstein as Class I Directors and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (RPID) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.